|
Mary Jean Stempien, MS, MD, FACP, joined Cerimon in June 2005 as its Vice President, Clinical Development. Dr. Stempien has over 15 years of clinical drug development experience obtained at Syntex Corp, Roche Pharmaceuticals, and most recently Tularik, Inc. (now part of Amgen), where she was Vice President, Clinical Development, with responsibility for development projects in all therapeutic areas (oncology, metabolism, and inflammation/immunology) and was a member of the Tularik senior management team. Prior to joining Tularik, she was responsible for one of four clinical units within the global development division of Roche Pharmaceuticals. Her development work contributed to approvals for two antiviral agents, Cytovene and Valcyte, and the transplant rejection agent CellCept. She has made company presentations at several FDA Advisory Committee hearings, all with successful outcomes. Dr. Stempien is a pharmacist, and received her medical degree from the University of Massachusetts Medical School. She is board-certified in Internal Medicine and is a Fellow of the American College of Physicians. | 